SBK Signs Strategic Collaboration with National Key Laboratory for Major Disease Novel Drug Development and Bounico Beijing to Advance Novel Drug R&D for Major Diseases

From December 13 to 15, 2024, the Second Annual Conference of the National Key Laboratory for Major Disease Novel Drug Target Discovery and Development took place in Ganzhou. Under the theme “Innovation Drives Development • Technology Empowers Industry”, the event brought together 13 academicians, 21 internationally renowned experts and professors, and more than 130 top national-level talents, including recipients of the National Science Fund for Distinguished Young Scholars and Yangtze River Scholars. Chengdu Shibeikang Biomedical Technology Co., Ltd. (SBK) was honored to be invited to participate in this prestigious event. During the conference, SBK signed a strategic cooperation agreement with the National Key Laboratory for Major Disease Novel Drug Development (referred to as the ‘Key Laboratory’) and Bounico Beijing Medical Technology Co., Ltd. (referred to as ‘Bounico’). This collaboration aims to jointly advance the R&D and technological transformation of novel drugs targeting major diseases, with a special focus on cardiovascular, cerebrovascular, and respiratory systems. The goal is to accelerate drug development and facilitate their clinical application and industrialization.

SBK is committed to the development of novel drugs that address critical global clinical needs, and is a leader in differentiated metabolic drug development. The company boasts a top-tier R&D team focused on overcoming challenges in drug development and pioneering the innovation of highly effective medicines. As a national-level research platform, the Key Laboratory has long been at the forefront of fundamental research and drug development for major diseases. Bounico, a professional medical technology service provider, has made significant achievements in drug evaluation and research, clinical practice guideline studies, and pharmaceutical policy research.

Through discussions with representatives from the Gannan Innovation and Translational Medicine Research Institute, SBK has established a comprehensive tripartite collaboration to create the Key Technology Research and Transformation Center for Drug Metabolism Differentiation under the National Key Laboratory of New Drug Innovation. This partnership is designed to enhance the R&D capabilities and translational efficiency of innovative drugs in critical areas such as cardiovascular, cerebrovascular, and respiratory diseases, with the aim of addressing unmet needs in disease prevention and treatment.

This strategic collaboration will not only accelerate drug development timelines but also provide more innovative treatment options for patients around the world, improving global disease prevention and treatment efforts. By combining the resources and expertise of all parties, the development of innovative drugs will be expedited, ensuring the timely translation of research breakthroughs into clinical treatments that can directly benefit patients.

The National Key Laboratory for Major Disease Novel Drug Development was jointly established by the Gannan Innovation and Translational Medicine Research Institute, the Air Force Medical University, and several other institutions. The laboratory brings together top experts and highly skilled professionals from across China’s biomedical field. Academician Chen Zhinan serves as the director, Professor Li Hongliang as the executive director, and Academician Yang Baofeng as the chief scientist. The academic committee includes 20 prominent academicians from the Chinese Academy of Sciences and the Chinese Academy of Engineering. In addition, more than 20 national-level talents, including Yangtze River Scholars and recipients of The National Science Fund for Distinguished Young Scholars, have actively contributed to the lab’s growth. A research team of over 500 members is dedicated to tackling major scientific challenges, such as the lack of original innovation in novel drug development in China. Their work includes forward-thinking, strategic, and systematic basic and applied translational research, focused on overcoming key core technological obstacles.

Bounico is a service organization specializing in medical research and clinical evaluation, covering various fields such as drug evaluation and research, clinical practice guideline studies, and pharmaceutical policy research. The company is dedicated to standardized clinical decision support and rational medication management, providing professional medical strategy system integration services for pharmaceutical companies and healthcare institutions, and facilitating the rapid translation of medical technologies.

Founded in 2015, Chengdu Shibeikang Biomedical Technology Co., Ltd. is a research-driven company rooted in China, serving the world and dedicated to differentiated drug innovation. Guided by our mission of “Empowering Better Health Through Inclusive Care and Support”, SBK is committed to the core values of “‘People-centered’, Driven by Change, Innovation at the Core”. Guided by clinical needs, we pursue an innovation-driven strategy with a focus on differentiated R&D. Specializing in cardiovascular, cerebrovascular, and respiratory therapies, we are dedicated to becoming a world leader in the differentiated innovation of novel drugs, developing better medicines to patients and advancing human health.